云南白药8月29日披露半年报，公司上半年实现营业收入212.57亿元，同比增长3.92%；归属于上市公司 股东的净利润36.33亿元，同比增长13.93%；基本每股收益2.04元。公司拟向全体股东每10股派发现金 红利10.19元（含税）。 ...

格隆汇8月29日丨云南白药(000538.SZ)公布2025年半年度报告，上半年公司实现营业收入212.57亿元， 同比增长3.92%；归属于上市公司股东的净利润36.33亿元，同比增长13.93%；归属于上市公司股东的扣 除非经常性损益的净利润34.61亿元，同比增长10.40%；基本每股收益2.04元；拟向全体股东每10股派 发现金红利10.19元(含税)。 ...

云南白药公告，2025年上半年营业收入212.57亿元，同比增长3.92%；归属于上市公司股东的净利润 36.33亿元，同比增长13.93%。公司拟向全体股东每10股派发现金红利10.19元（含税）。 (本文来自第一财经) ...

Investment Rating - The report maintains a "Buy" rating for the company [6][8]. Core Views - The company experienced significant revenue and profit pressure in the first half of 2025, with revenue, net profit attributable to shareholders, and net profit excluding non-recurring items declining by 27%, 40%, and 46% year-on-year, respectively [1][2]. - Despite the current challenges, the company is expected to gradually narrow the revenue decline, with potential growth from its traditional Chinese medicine, biopharmaceuticals, and chemical drugs pipelines [1][2]. - The collaboration with Dong'e Ejiao to promote Huangqi Essence is anticipated to unlock market potential, leveraging Dong'e Ejiao's strong marketing and distribution capabilities [4]. Summary by Sections Financial Performance - In 1H25, the company's revenue was 1.64 billion RMB, with a net profit of 140 million RMB and a net profit excluding non-recurring items of 120 million RMB, reflecting a year-on-year decline of 27%, 40%, and 46%, respectively [1]. - In 2Q25, revenue was 764 million RMB, with a net profit of 59 million RMB and a net profit excluding non-recurring items of 38 million RMB, showing declines of 15%, 42%, and 53% year-on-year [1]. Product Performance - Core products faced sales pressure, with injection revenue down 40% to 510 million RMB and oral liquid revenue down 49% to 280 million RMB in 1H25 [2]. - Other dosage forms showed mixed performance, with capsules and granules experiencing declines of approximately 5% and 18%, while tablets, patches, and gels saw growth of 5% to 12% [2]. Research and Development - The company has a robust R&D pipeline, with two approved traditional Chinese medicines and several in various clinical trial phases [5]. - The acquisition of Zhongxin Pharmaceutical is expected to enhance the company's product offerings, particularly in diabetes treatment with unique dual-target and triple-target products [3]. Valuation and Forecast - The revenue forecast for 2025-2027 has been adjusted downwards by 8%, 11%, and 13%, respectively, with expected net profits of 400 million RMB, 460 million RMB, and 530 million RMB, reflecting year-on-year growth of 2%, 15%, and 15% [6]. - The target price is set at 21.26 RMB, based on a 30x PE for 2025, indicating a premium over the average PE of comparable companies [6].

人民财讯8月29日电，云南白药（000538）8月29日晚间发布半年报，2025年上半年，公司实现营业收入 212.57亿元，同比增长3.92%；归母净利润36.33亿元，同比增长13.93%；基本每股收益2.04元；拟每10 股派发现金红利10.19元(含税)。 ...

智通财经APP讯，同仁堂(600085.SH)披露2025年半年度报告，报告期公司实现营收97.69亿元，同比增 长0.06%;归母净利润9.45亿元，同比下降7.39%;扣非净利润9.42亿元，同比下降5.03%;基本每股收益 0.689元。 ...

Core Viewpoint - The company has announced a profit distribution plan for the first half of 2025, proposing a cash dividend of 1.40 yuan per share, which reflects a significant return to shareholders based on its financial performance [1][2]. Summary by Sections Profit Distribution Plan - The company plans to distribute a cash dividend of 14.00 yuan for every 10 shares held, amounting to a total cash dividend of 844,644,094.00 yuan (including tax) based on a total share count of 603,317,210 shares as of June 30, 2025 [2]. - This cash dividend represents 58.56% of the net profit attributable to shareholders in the consolidated financial statements for the first half of 2025, which is 1,442,309,309.94 yuan [2]. Decision-Making Process - The profit distribution plan was authorized by the shareholders' meeting, allowing the board of directors to decide on the profit distribution scheme for 2025, provided it meets the profit distribution conditions [2]. - The board of directors approved the profit distribution plan with unanimous support during its meetings, with 7 votes in favor and no opposition [2]. - The supervisory board also approved the plan, indicating that it aligns with the company's operational performance, cash flow, and funding needs, ensuring reasonable returns to shareholders [3]. Additional Notes - The company will adjust the per-share distribution amount if there are changes in the total share capital before the record date for the dividend distribution, but the total distribution amount will remain unchanged [1][2].

Core Viewpoint - The company has approved a profit distribution plan for the first half of 2025, which includes a cash dividend and share buyback, reflecting its commitment to shareholder returns while considering its financial health and operational needs [1][2][3] Group 1: Profit Distribution Plan - The company plans to distribute a total cash dividend of 351,714,476.10 yuan, with the total profit available for distribution amounting to 20,714,325,548.04 yuan [1] - The net profit for the first half of 2025 is reported at 1,232,198,036.53 yuan, leading to a total distributable profit of 20,265,496,692.04 yuan after accounting for the cash dividend [1] - The total cash dividend and share buyback amount to 354,477,122.08 yuan, which represents 27.66% of the net profit attributable to shareholders for the first half of 2025 [2] Group 2: Compliance and Reasoning - The profit distribution plan adheres to the regulations set by the China Securities Regulatory Commission and the Shenzhen Stock Exchange, ensuring that the distribution does not exceed the lower of the profits available in the consolidated or parent company financial statements [2] - The cash dividend plan is justified by considering industry characteristics, development stage, operational model, profitability, debt repayment capacity, and capital needs, aiming for sustainable business growth and comprehensive shareholder returns [3] - The plan is deemed legal, compliant, and reasonable, with no detriment to the interests of the company or its shareholders [3]

格隆汇8月29日丨吉林敖东(000623.SZ)公布2025年半年度报告，上半年公司实现营业收入11.26亿元，同 比下降20.21%；归属于上市公司股东的净利润12.82亿元，同比增长138.44%；归属于上市公司股东的扣 除非经常性损益的净利润11.67亿元同比增长43.68%；基本每股收益1.0915元；拟向全体股东每10股派 发现金红利2.00元(含税)。 ...

格隆汇8月29日丨片仔癀(600436.SH)公布，2025年上半年，公司实现营业收入53.79亿元，同比下降 4.81%；归属于上市公司股东的净利润14.42亿元，同比下降16.22%。公司拟向全体股东每10股派发现金 红利14元（含税）。 ...